Current insights into ocular graft-versus-host disease

Current Opinion in Ophthalmology

Volumn 21, Issue 6, 2010, Pages 485-494

  Riemens, Anjo ^a   Te Boome, Liane ^a   Imhof, Saskia ^a   Kuball, Jürgen ^a   Rothova, Aniki ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

ocular graft versus host disease; ocular surface disease; treatment

Indexed keywords

ANTIINFLAMMATORY AGENT; ARTIFICIAL TEAR; CYCLOSPORIN A; STEROID; TACROLIMUS; TRANILAST;

ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW DISEASE; CLINICAL FEATURE; CONTACT LENS; DRUG EFFICACY; EYE DISEASE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; TREATMENT INDICATION;

EYE DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 78049290885     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32833eab64     Document Type: Review

References (59)

1. Balaram M, Rashid S, Dana R. Chronic ocular surface disease after allogeneic bone marrow transplantation. Ocul Surf 2005; 3:203-211.
2. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373:1550-1561.
3. Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114:702-708.
4. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69:204-217.
5. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11:945-956. (Pubitemid 41754712)
6. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008; 1:134-141.
7. Couriel DR. Ancillary and supportive care in chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21:291-307.
8. Filipovich AH. Diagnosis and manifestations of chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21:251-257.
9. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313:765-771.
10. Hale G, Slavin S, Goldman JM, et al. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? Bone Marrow Transplant 2002; 30:797-804.
11. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25:139-170.
12. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7:340-352.
13. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006; 43:3-10.
14. Dustin ML. Role of adhesion molecules in activation signaling in T lymphocytes. J Clin Immunol 2001; 21:258-263.
15. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood 2009; 114:4919-4927.
16. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77:1423-1428.
17. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34:621-625.
18. Storb R, Pepe M, Anasetti C, et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 1990; 76:1037-1045.
19. Antin JH. Approaches to graft-vs-host disease. Pediatr Transplant 2005; 9 (Suppl 7):71-75.
20. Antin JH, Chen AR, Couriel DR, et al. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2004; 10:655-668.
21. Le BK, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439-1441.
22. Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 2007; 20:281-294.
23. Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009; 114:709-718.
24. Westeneng AC, Hettinga Y, Lokhorst H, et al. Ocular graft-versus-host disease after allogeneic stem cell transplantation. Cornea 2010; 7:758-763.
25. Saito T, Shinagawa K, Takenaka K, et al. Ocular manifestation of acute graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Int J Hematol 2002; 75:332-334.
26. Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea 2003; 22:S19-S27.
27. Tabbara KF, Al-Ghamdi A, Al-Mohareb F, et al. Ocular findings after allogeneic hematopoietic stem cell transplantation. Ophthalmology 2009; 116:1624-1629.
28. Franklin RM, Kenyon KR, Tutschka PJ, et al. Ocular manifestations of graft-vs-host disease. Ophthalmology 1983; 90:4-13.
29. Hirst LW, Jabs DA, Tutschka PJ, et al. The eye in bone marrow transplantation. I: Clinical study. Arch Ophthalmol 1983; 101:580-584.
30. Jabs DA, Hirst LW, Green WR, et al. The eye in bone marrow transplantation. II: Histopathology. Arch Ophthalmol 1983; 101:585-590.
31. Jabs DA, Wingard J, Green WR, et al. The eye in bone marrow transplantation. III: Conjunctival graft-vs-host disease. Arch Ophthalmol 1989; 107:1343-1348. (Pubitemid 19229080)
32. Westekemper H, Meller S, Citak S, et al. Differential chemokine expression in chronic GVHD of the conjunctiva. Bone Marrow Transplant 2010. [Epub ahead of print]
33. Jack MK, Hicks JD. Ocular complications in high-dose chemoradiotherapy and marrow transplantation. Ann Ophthalmol 1981; 13:709-711.
34. Russo PA, Bouchard CS, Galasso JM. Extended-wear silicone hydrogel soft contact lenses in the management of moderate to severe dry eye signs and symptoms secondary to graft-versus-host disease. Eye Contact Lens 2007; 33:144-147.
35. Takahide K, Parker PM, Wu M, et al. Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13:1016-1021.
36. Ogawa Y, Yamazaki K, Kuwana M, et al. A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD. Invest Ophthalmol Vis Sci 2001; 42:111-119.
37. Rojas B, Cuhna R, Zafirakis P, et al. Cell populations and adhesion molecules expression in conjunctiva before and after bone marrow transplantation. Exp Eye Res 2005; 81:313-325.
38. Moon SJ, Mieler WF. Retinal complications of bone marrow and solid organ transplantation. Curr Opin Ophthalmol 2003; 14:433-442.
39. Kim SK. Update on ocular graft versus host disease. Curr Opin Ophthalmol 2006; 17:344-348.
40. Coskuncan NM, Jabs DA, Dunn JP, et al. The eye in bone marrow transplantation. VI: Retinal complications. Arch Ophthalmol 1994; 112:372-379.
41. Hettinga YM, Verdonck LF, Fijnheer R, et al. Anterior uveitis: a manifestation of graft-versus-host disease. Ophthalmology 2007; 114:794-797.
42. Wertheim M, Rosenbaum JT. Bilateral uveitis manifesting as a complication of chronic graft-versus-host disease after allogeneic bone marrow transplantation. Ocul Immunol Inflamm 2005; 13:403-404.
43. Robinson MR, Lee SS, Rubin BI, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant 2004; 33:1031-1035.
44. Doughty MJ, Glavin S. Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol Opt 2009; 29:573-583.
45. Chiang CC, Lin JM, Chen WL, Tsai YY. Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea 2007; 26:861-863.
46. Fox RI, Chan R, Michelson JB, et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984; 27:459-461.
47. VanSetten GB, Viinikka L, Tervo T, et al. Epidermal growth factor is a constant component of normal human tear fluid. Graefes Arch Clin Exp Ophthalmol 1989; 227:184-187.
48. Ogawa Y, Okamoto S, Mori T, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31:579-583.
49. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology 2005; 112:1790-1794.
50. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 StudyGroup. Ophthalmology 2000; 107:631-639.
51. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000; 107:967-974.
52. Kiang E, Tesavibul N, Yee R, et al. The use of topical cyclosporin A in ocular graft-versus-host-disease. Bone Marrow Transplant 1998; 22:147-151.
53. Lelli GJ Jr, Musch DC, Gupta A, et al. Ophthalmic cyclosporine use in ocular GVHD. Cornea 2006; 25:635-638.
54. Rao SN, Rao RD. Efficacy oftopical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease. Cornea 2006; 25:674-678.
55. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987; 40:1249-1255.
56. Ogawa Y, Okamoto S, Kuwana M, et al. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea 2001; 20:430-434.
57. Tam PM, Young AL, Cheng LL, Lam PT. Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. Bone Marrow Transplant 2010; 45:957-958.
58. Ogawa Y, Dogru M, Uchino M, et al. Topical tranilast for treatment of the early stage of mild dry eye associated with chronic GVHD. Bone Marrow Transplant 2010; 45:565-569.
59. Smith VA, Khan-Lim D, Anderson L, Cook SD. Dick AD: Does orally administered doxycycline reach the tear film? Br J Ophthalmol 2008; 92:856-859.